Retro Bio valuation, funding and investors
Retro Bio works in aging-related disease therapies development, based in Redwood City, United States. It has about 99 employees.
- Last round
- Series A · $1.00B · Jan 2025
- Valuation at last round
- $5.00B
- Headcount
- 99 · growing
- Grade
- B
- Founded
- –
Retro Bio valuation today
VCMC values Retro Bio at $10.0B today, with a range of $5.4B to $11.5B and a grade of B. The valuation starts from its last funding round, a Series A round in Jan 2025.
Valuation by date (56 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jun 2022 | $1.0B | $657M – $3.0B | $2.0B (+100%) | after a round | – | unknown | C | 0% |
| 2 Jun 2022 | $1.0B | $657M – $3.0B | $2.0B (+100%) | after a round | – | unknown | C | 0% |
| 1 Jul 2022 | $1.1B | $657M – $3.0B | $2.0B (+89%) | after a round | – | unknown | C | 0% |
| 1 Aug 2022 | $1.1B | $657M – $3.0B | $2.0B (+78%) | after a round | – | unknown | C | 0% |
| 1 Sep 2022 | $1.2B | $657M – $3.0B | $2.0B (+68%) | after a round | – | unknown | C | 0% |
| 1 Oct 2022 | $1.3B | $657M – $3.0B | $2.0B (+59%) | after a round | – | unknown | C | 0% |
| 1 Nov 2022 | $1.3B | $657M – $3.0B | $2.0B (+50%) | after a round | – | unknown | C | 0% |
| 1 Dec 2022 | $1.4B | $657M – $3.0B | $2.0B (+41%) | after a round | 23 | unknown | C | 0% |
| 1 Jan 2023 | $1.5B | $657M – $3.0B | $2.0B (+33%) | after a round | 23 | unknown | C | 0% |
| 1 Feb 2023 | $1.6B | $657M – $3.0B | $2.0B (+26%) | after a round | 23 | unknown | C | 0% |
| 1 Mar 2023 | $1.7B | $657M – $3.0B | $2.0B (+19%) | after a round | 23 | unknown | C | 0% |
| 1 Apr 2023 | $1.8B | $657M – $3.0B | $2.0B (+12%) | after a round | 23 | unknown | C | 0% |
| 1 May 2023 | $1.9B | $657M – $3.0B | $2.0B (+6%) | after a round | 23 | unknown | C | 0% |
| 1 Jun 2023 | $2.0B | $657M – $3.0B | $2.0B (0%) | after a round | 23 | unknown | C | 0% |
| 1 Jul 2023 | $2.0B | $626M – $3.0B | $2.0B (0%) | after a round | 23 | unknown | C | 0% |
| 1 Aug 2023 | $2.0B | $595M – $3.0B | $2.0B (0%) | after a round | 23 | unknown | C | 0% |
| 1 Sep 2023 | $2.0B | $565M – $3.0B | $2.0B (0%) | after a round | 23 | unknown | C | 0% |
| 1 Oct 2023 | $2.0B | $668M – $3.0B | $2.0B (0%) | after a round | 46 | growing | C | 0% |
| 1 Nov 2023 | $2.0B | $671M – $3.0B | $2.0B (0%) | after a round | 46 | growing | C | 0% |
| 1 Dec 2023 | $2.0B | $674M – $3.0B | $2.0B (0%) | after a round | 46 | growing | C | 0% |
| 1 Jan 2024 | $2.0B | $677M – $3.0B | $2.0B (0%) | after a round | 46 | growing | C | 0% |
| 1 Feb 2024 | $2.0B | $680M – $3.0B | $2.0B (0%) | after a round | 46 | growing | C | 0% |
| 1 Mar 2024 | $2.0B | $683M – $3.0B | $2.0B (0%) | after a round | 52 | growing | C | 0% |
| 1 Apr 2024 | $2.0B | $686M – $3.0B | $2.0B (0%) | after a round | 52 | growing | C | 0% |
| 1 May 2024 | $2.0B | $689M – $3.0B | $2.0B (0%) | after a round | 52 | growing | C | 0% |
| 1 Jun 2024 | $2.0B | $621M – $3.0B | $2.0B (0%) | after a round | 52 | growing | C | 0% |
| 1 Jul 2024 | $2.0B | $374M – $3.0B | $2.0B (0%) | after a round | 52 | up | D | 0% |
| 1 Aug 2024 | $2.0B | $358M – $3.0B | $2.0B (0%) | after a round | 58 | up | D | 0% |
| 1 Sep 2024 | $2.0B | $343M – $3.0B | $2.0B (-1%) | after a round | 58 | up | D | 0% |
| 1 Oct 2024 | $2.0B | $328M – $3.0B | $2.0B (-1%) | after a round | 58 | up | D | 0% |
| 1 Nov 2024 | $2.0B | $314M – $3.0B | $2.0B (0%) | after a round | 61 | up | D | 0% |
| 1 Dec 2024 | $2.0B | $301M – $3.0B | $2.0B (0%) | after a round | 61 | up | D | 0% |
| 1 Jan 2025 | $5.0B | $4.3B – $10.4B | $9.0B (+80%) | after a round | 61 | up | B | 0% |
| 2 Jan 2025 | $5.0B | $4.3B – $10.4B | $9.0B (+80%) | after a round | 61 | up | B | 0% |
| 1 Feb 2025 | $5.3B | $4.3B – $10.4B | $9.0B (+71%) | after a round | 61 | up | B | 0% |
| 1 Mar 2025 | $5.5B | $4.3B – $10.4B | $9.0B (+64%) | after a round | 61 | up | B | 0% |
| 1 Apr 2025 | $5.8B | $4.3B – $10.4B | $9.0B (+56%) | after a round | 61 | up | B | 0% |
| 1 May 2025 | $6.1B | $4.3B – $10.4B | $9.0B (+48%) | after a round | 61 | up | B | 0% |
| 1 Jun 2025 | $6.4B | $4.3B – $10.4B | $9.0B (+41%) | after a round | 61 | up | B | 0% |
| 1 Jul 2025 | $6.8B | $4.3B – $10.7B | $9.3B (+37%) | after a round | 72 | growing | B | 0% |
| 1 Aug 2025 | $7.2B | $4.3B – $10.8B | $9.4B (+30%) | after a round | 74 | growing | B | 0% |
| 1 Sep 2025 | $7.6B | $4.3B – $10.8B | $9.4B (+23%) | after a round | 74 | growing | B | 0% |
| 1 Oct 2025 | $8.0B | $4.3B – $10.8B | $9.4B (+17%) | after a round | 74 | up | B | 0% |
| 1 Nov 2025 | $8.5B | $4.3B – $10.9B | $9.4B (+11%) | after a round | 76 | up | B | 0% |
| 1 Dec 2025 | $8.9B | $4.3B – $10.9B | $9.4B (+6%) | after a round | 76 | up | B | 0% |
| 1 Jan 2026 | $9.4B | $4.3B – $10.9B | $9.4B (0%) | after a round | 76 | up | B | 0% |
| 1 Feb 2026 | $9.6B | $4.4B – $11.1B | $9.6B (0%) | after a round | 83 | growing | B | 0% |
| 1 Mar 2026 | $9.6B | $4.5B – $11.1B | $9.6B (0%) | after a round | 83 | growing | B | 0% |
| 1 Apr 2026 | $9.6B | $4.6B – $11.1B | $9.6B (0%) | after a round | 83 | growing | B | 0% |
| 1 May 2026 | $9.9B | $4.7B – $11.4B | $9.9B (0%) | after a round | 96 | growing | B | 0% |
| 1 Jun 2026 | $9.9B | $4.3B – $11.4B | $9.9B (0%) | after a round | 96 | up | B | 0% |
| 1 Jul 2026 | $9.9B | $4.3B – $11.4B | $9.9B (0%) | after a round | 96 | up | B | 0% |
| 1 Aug 2026 | $10.0B | $4.3B – $11.5B | $10.0B (0%) | after a round | 97 | up | B | 0% |
| 1 Sep 2026 | $10.0B | $4.3B – $11.5B | $10.0B (0%) | after a round | 97 | up | B | 0% |
| 1 Oct 2026 | $10.0B | $5.3B – $11.5B | $10.0B (0%) | after a round | 99 | growing | B | 0% |
| 24 Oct 2026 | $10.0B | $5.4B – $11.5B | $10.0B (0%) | after a round | 99 | growing | B | 0% |
Key facts about Retro Bio
- Founded
- Not on record
- Headquarters
- Redwood City, United States
- Employees
- about 99 +34% in a year
- Total raised
- $1.18B
- Funding rounds
- 2
- Last round
- Series A Jan 2025
Retro Bio was founded by Joe Betts-LaCroix, Matt Buckley and Sheng Ding.
Retro Bio funding history
Retro Bio has 2 funding rounds on record, from Jun 2022 to Jan 2025, $1.18B in total. The latest disclosed valuation is $5.00B post-money (Series A, Jan 2025).
Series A 1 Jan 2025
With OpenAI, Sam Altman.
Sources: longevityinvestorsnews.ch, techcrunch.com, thelongevityinitiative.org
$1.00B
$5.00B post-money
$180M
Retro Bio investors
2 investors have backed Retro Bio.
- OpenAI
- Sam Altman
What Retro Bio does
Retro Bio works in biotechnology, with 10 recorded offerings and customers in healthcare and biotechnology.
Retro Biosciences is a United States biotechnology company engaged in the development of therapies aimed at extending human lifespan and preventing age-related diseases. The company focuses on cellular reprogramming and autophagy to rejuvenate cell and tissue function, and utilizes single-cell multi-omics, pooled perturbations, and targeted delivery systems to intervene in aging processes. Retro Bio operates as a generational pharmaceutical company, with a portfolio of research and development activities focused on aging mechanisms and the potential for human translation.
Description from Veridion's company data.
Products and services
- Aging-Related Disease Therapies Development
- Cellular Reprogramming Therapies Development
- Autophagy-Inducing Therapies Development
- Single-Cell Multi-Omics Research and Development
- Pooled Perturbation Screening Research and Development
- Targeted Delivery System Development
- Aging Mechanism Identification and Validation
- Mammalian Aging Model Research and Development
- Human Aging Therapy Translation
- Generational Pharmaceutical Innovation Services
Markets
- Healthcare
- Biotechnology
Technology
- Single-Cell Multi-Omics
- Pooled Perturbations
- Targeted Delivery Systems
- Cellular Reprogramming
- Autophagy Therapies
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Retro Bio
What is Retro Bio worth?
Valuation $10.0B (range $5.4B to $11.5B), as of 24 Oct 2026. The last disclosed valuation was $5.00B (Series A, Jan 2025).
Has Retro Bio raised money?
Retro Bio has 2 funding rounds on record, from Jun 2022 to Jan 2025, $1.18B in total. The latest disclosed valuation is $5.00B post-money (Series A, Jan 2025).
Who has invested in Retro Bio?
OpenAI and Sam Altman.
How many people work at Retro Bio?
About 99, up 34% over the last year. Headcount grew from 23 in Dec 2022 to 99 in Sep 2026.
What does Retro Bio do?
Retro Bio works in biotechnology, with 10 recorded offerings and customers in healthcare and biotechnology. Its main offerings are aging-related disease therapies development, cellular reprogramming therapies development and autophagy-inducing therapies development.
Where is Retro Bio based?
Retro Bio is based in Redwood City, United States; its founding year is not on record. It has about 99 employees, up 34% over the last year.